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ABSTRACT 
Atropine has been used for more than a century to arrest myopia progression. Compelling evidence of its protective 
effect has been reported in well-designed clinical studies, mainly performed during the last two decades. However, its 
exact mechanism of action has not been determined. Experimental findings have shown that the mechanism is not 
related to accommodation, as was thought for decades. A review of the published literature revealed a significant 
amount of evidence supporting its safety and efficacy at a concentration of 1.0%, and at lower concentrations (as low as 
0.01%). 
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INTRODUCION
During the preceding decades, a noteworthy increase in 
myopia prevalence has been reported in many countries, 
including in Southeast Asia. This increase, which has 
occurred over only 25 to 50 years, has focused renewed 
attention on the crucial effect of environmental factors 
and has prompted a growing interest in pharmacological 
treatments that can help stop the progression of myopia 
(1-7). 
In 1611, Kepler proposed his hypothesis of near work as 
the cause of myopia, suggesting that reading and 
performing visual tasks at short distances in childhood 
accustomed the eye to near objects (8-10). Due to 
Kepler’s work, accommodation was linked to myopia. 
Several mechanisms related to accommodation and/or 
convergence were proposed during the next two 
centuries (11, 12). The good, well-documented results 
that were obtained using bilateral atropine treatments 
during the 20th century demonstrated that convergence 
likely has no effect on myopia onset or progression, as 
children receiving bilateral atropine continued to 
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perform near-vision work, and therefore converge, but 
the severity of myopia did not increase (13-16). In 
addition, experimental evidence against accommodation 
as a primary determinant in the etiology of myopia has 
recently emerged, including the finding that 
experimental myopia could be induced in primates even 
after destruction of the ciliary ganglion or the Edinger-
Westphal nucleus, which eliminated the accommodative 
reflex (17). Stone et al. (1991) reported that atropine 
attenuated the excessive axial elongation related to form 
deprivation in chicks, although they do not have 
muscarinic receptors in the ciliary body (18). McBrien et 
al. (1993) showed that it was possible to induce 
experimental myopia in small mammals (grey squirrels) 
that do not have a functional accommodative system 
(19). The same author in the same year also reported, in 
accordance with the findings of Stone et al., that atropine 
slowed the development of experimental myopia in 
chicks, indicating that a non-accommodative mechanism 
was involved in experimental myopia onset and 
progression, since ciliary muscle in chicks contracts 
through a nicotinic not a muscarinic mechanism (20). 
Modern epidemiological studies have produced 
contradictory results concerning near work and myopia. 
Several studies have found that near work is related to a 
higher prevalence and degree of myopia (21-29); children 
who read uninterruptedly or at a closer distance have a 
higher probability of being myopic, and stabilization of 
myopia by the age of 15 years may potentially be 
associated with less time spent on near work activities 
(27, 30, 31). However, other findings have not supported 
a significant effect of near work on myopia (21, 29, 32-
37). In the Orinda Longitudinal Study of Myopia, Jones et 
al. studied a group of children from California, U.S.A. and 
found that near work (reading, watching television, 
studying, using the computer, or playing video games) 
was not a significant risk factor in myopia onset (32). In 
the Singapore Cohort Study of the Risk Factors for 
Myopia (SCORM), Saw et al. thoroughly assessed near 
work (books per week, hours per day of reading, 
computer use, playing video games, and watching 
television) and also found that none of these variables 
was a significant risk factor for myopia (33, 34). Very 
recently, Zadnik et al. used data from the collaborative 
longitudinal evaluation of ethnicity and refractive error 
(CLEERE) Study in the United States (including Caucasian, 
African-American, Hispanic, and Asian children) and 
found that near work was not predictive of myopia 
onset, either in univariate or multivariate models (37). 
HERITABILITY VERSUS ENVIRONMENT IN MYOPIA 
Heritability has been identified for more than a century 
as an influencing factor, and its link to myopia has been 
confirmed by many genetic and epidemiological studies 
during the last 50 years (7, 12, 38-46). However, as 
individuals from the same family frequently share 
common environmental conditions, heritability studies 
can reflect overestimations (7, 42, 43). The discovery of 
more than 40 genetic loci related to the development of 
myopia has supported the existence of a genetic 
contribution to this condition (1, 41, 42, 47, 48); one 
important predictor for the onset of myopia is a parental 
history of myopia (21, 37, 43, 49-55). In the SCORM 
study, Saw et al. found that schoolchildren with two 
myopic parents had an increased risk of myopia (1.6 
times) compared to children with no myopic parent (32, 
34, 42, 43, 49). In addition, according to the recently 
reported results of the Growing Up in Singapore towards 
healthy outcomes (GUSTO) study, Chua et al. suggested 
that genetic factors may have a larger impact on the 
early development of refractive error than 
environmental factors. In multivariable regression 
models, 3-year-old children with two myopic parents 
were more likely to have a more myopic spherical 
equivalent and longer axial length, and to be more likely 
to have myopia, than children whose parents were not 
myopic (56). However, other researchers explain that 
while this relationship is compatible with the idea of a 
genetic basis for myopia, it does not establish a definitive 
relationship because, as previously mentioned, parents 
and their children also share common environmental 
factors (7). In addition, the influence of parental myopia 
on the refractive error of schoolchildren and teenagers 
has not been a universal finding. In 1886, Cohn found 
that only 2.7% of 1,004 myopic schoolchildren reported 
that one of their parents was myopic or possibly myopic 
(12). Quek et al. (2004) reported no statistical difference 
in myopia incidence in students aged 15-19 years 
according to parental history (57). However, both 
studies, performed more than a century apart, had the 
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limitation that the parental refractive status was 
established by questioning the children and teenagers 
rather than the parents (12, 57). The interaction between 
heredity and environment has been a subject of 
controversy for long time (12, 44, 45). In a three-
generation study of children from Hong Kong and 
Northern China, Wu and Edwards found that the 
influence of family history (at least one myopic parent) 
on the risk of having myopia was higher in the second 
generation (parents’ generation), than in the third 
generation (children’s generation). This finding supports 
a stronger effect of environmental factors than 
heritability on the development of myopia (7, 54). 
Pioneering studies by Wiesel and Raviola in the late 
1970s and later studies by Wallman and coworkers 
confirmed that deprivation of visual stimulus caused 
myopia in young animals in multiple species (58, 59). 
Those experiments demonstrated the effect of 
environment on the refractive status of the eye in 
animals, but this does not necessarily indicate that 
human myopia is largely environmental (2, 58-60). 
Current evidence, including experimental studies, seems 
to support the premise that juvenile myopia 
development is driven by both genetic and 
environmental factors (34, 43, 51, 61-64). However, the 
mechanism by which genes identified as responsible for 
experimental myopia determine the appearance of that 
refractive error in humans has not yet been determined 
(51, 61, 65). Mutti et al. (1996) discussed the nature 
versus nurture debate as each affects the development 
of myopia. Traditionally, it was assumed that one or the 
other affected the development of myopia. Now, it 
appears that both do, and research is being conducted to 
examine the extent of the effect each one has (66). 
Morgan and Rose (2005) reported that high heritability 
does not indicate an established limit to possible changes 
generated by environmental factors. They indicated that 
the concept that populations of East Asian origin have a 
genetically determined higher risk of myopia was not 
supported by the low prevalence reported in populations 
in non-urban areas of several countries in the region 
(Mainland China, Taiwan, Japan, and Singapore), or by 
the high rate of myopia found among other ethnic 
groups (including Indians) with different genetic 
information migrating to Southeast Asia (7, 67-70). 
Examples of low prevalence of myopia in East Asian 
people include the report by Chang et al., who cited a 
study by Chen, performed in the 1980s, that found only a 
9.7% prevalence of myopia in non-aboriginal students in 
Taiwan (69). Lin et al. reported a rate of myopia of 20% 
among aboriginal schoolchildren (68). More recent 
findings in China and Singapore also seem to support that 
East Asian people do not have a significantly higher 
genetic predisposition for myopia than other ethnic 
groups, as low prevalence estimates have been reported 
in some ethnic groups from those countries (71-74). In 
addition, the premise that an East Asian genetic 
background may increase susceptibility to risk factors 
does not seem to be valid considering the recently 
reported findings of a significant increase in myopia in 
young adults of Indian origin living in Singapore over a 
period of 13 years (1996-1997 and 2009-2010) (3). This 
increase in prevalence in Indian individuals was higher 
than in individuals of Chinese and Malay ethnic groups of 
the same age (3). However, myopia in India is much less 
prevalent (75). These findings suggest that 
environmental conditions, including intensive education 
and limited time spent outdoors, are directly related to 
the high prevalence of myopia in all ethnic groups of 
Singapore, indicating that genetic influence may not be 
very important (7, 67, 68, 74). A propensity to develop 
myopia in so-called ‘‘myopigenic’’ milieus seems to be a 
feature common to most humans (7, 66, 74). Detailed 
reviews of the research into the genetics of myopia have 
been published elsewhere by different authors (47, 51, 
61, 76-79). 
ATROPINE USE IN THE CONTROL OF MYOPIA 
By the mid-1800s, atropine was frequently used in 
ophthalmology for pupillary dilation to examine the 
posterior segment of the eye and as a temporary 
treatment to improve vision in cases of cataracts. It was 
also used to induce mydriasis during cataract surgery and 
to prevent or break the posterior synechia in cases of 
uveitis. At that time, it was not used in myopia treatment 
(80-82). 
Donders (1864) was the first to recommend atropine as a 
treatment for myopia when he suggested it for suspected 
spasms of accommodation in myopic patients (11). One 
hundred years ago, Pollock was the first to employ 
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prolonged use of atropine for the treatment of myopia 
(for a duration of several months to almost a year); the 
therapy also required affected children to avoid reading 
and writing (13, 83, 84). However, in the following 
decades of the 20th century, pharmacological treatment 
of myopia was not pursued. Few researchers from the 
1930s to the 1990s conducted new studies (85-97). As 
previously mentioned, several of those studies 
completely disproved the hypothesis of convergence as 
the main cause of myopia, as children in those studies 
continued to read with both eyes, and therefore 
converge, with no signs of worsening myopia. In spite the 
evidence of the effectiveness of atropine treatment, it 
was not popular among ophthalmologists and had 
notable detractors (98-101). 
A compelling body of evidence has recently emerged 
from several well-designed studies, including large 
groups of children, mainly from Asia. Shih et al. (1999) 
studied the daily use of different concentrations of 
atropine in 186 schoolchildren followed for up to two 
years (102). They found that the mean progression of 
myopia was 0.04 ± 0.63 diopter (D) per year in the group 
receiving a solution of 0.5% atropine; 0.45 ± 0.55 D per 
year in the group that received 0.25% atropine; 0.47 ± 
0.91 D per year in the 0.1% atropine group, and 1.06 ± 
0.61 D per year in the control group who received 0.5% 
tropicamide. They concluded that although all three 
concentrations of atropine had a significant protective 
effect with regard to slowing myopia progression, 0.5% 
atropine was the most effective (102). In 2001, the same 
researchers reported the results of another clinical trial 
that evaluated the effects of atropine with multifocal 
lenses to decrease the progression rate of myopia in 188 
children assigned to three treatment groups. The first 
group was treated with daily 0.5% atropine 
concomitantly with use of multi-focal eyeglasses, the 
second group used only multi-focal eyeglasses, and the 
third group used single vision eyeglasses. The study had a 
follow-up time of at least 18 months. The researchers 
found that over 18 months, the mean progression of 
myopia in the group treated with atropine and multi-
focal eyeglasses (0.42 D) was significantly less than the 
multi-focal (1.19 D) and single-vision groups (1.40 D) 
(103). The study Atropine in the Treatment of Myopia 
(ATOM 1) by Chua et al. (2006) was a randomized, 
double-blind, placebo-controlled trial including 400 
children. It showed that 1.0% atropine eye drops applied 
daily in one eye over a period of 24 months reduced the 
progression of myopia by 77% compared with the 
untreated eye (1.2 D in the control group compared to 
0.28 D in eyes treated with atropine) (104). The primary 
effect of atropine appeared to be by slowing the growth 
of vitreous chamber depth, which in turn decelerate axial 
length increase (105). 
Both concentration and frequency of atropine have been 
modified to minimize the side effects while trying to 
maintain the benefits. Chou et al. (1997) proposed that 
application of 0.5% atropine eye drops once per day was 
effective for slowing the progression of refractive error, 
even in children with severe myopia (106). As mentioned 
earlier, this group of researchers had also compared 
different concentrations of atropine and concluded that 
although 0.5% atropine was the most effective, the 
dropout rate may have reduced its effectiveness. 
Therefore, in 1999 it was suggested that because daily 
drops of 0.1% and 0.25% atropine were well-tolerated, 
those concentrations could be used initially to control 
the progression of myopia in children with rapid 
progression or in those who tended to have severe or 
early-onset myopia (102). More than a decade later, two 
additional studies that used low-concentration atropine 
and included medium-term follow-up were published. 
Wu et al. (2011) studied a group of 117 children (97 
children received 0.05% or 0.1% atropine, 20 children 
were included as a control group). The mean follow-up 
length was 4.5 years. They used for analysis a model 
containing both fixed and random effects (mixed model) 
and found that the adjusted progression of myopia in the 
treated group was significantly lower than that of the 
control group (-0.23 D versus -0.86 D per year) (107). In 
2012 the results of the Atropine for the Treatment of 
Myopia 2 (ATOM 2) study indicated that the efficacy of a 
very low concentration (0.01%) atropine applied once 
nightly did not significantly differ from that of 0.1% and 
0.5% atropine solutions for control of myopia 
progression, and had minimal side effects (108). The 
ATOM 2 study reported that over two years, the mean 
progression was −0.30 D in the 0.5% group, −0.38 D in 
the 0.1% group, and −0.49 D in the 0.01% group. All 
groups had progression significantly lower than the 
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control group reported in the ATOM 1 study, which was -
1.20 D for the same two-year period. However, cessation 
of treatment  often resulted in a myopic rebound effect, 
which was more pronounced in eyes that received 1.0%, 
0.5% and 0.1% atropine than in eyes that received 0.01% 
atropine (109). Recently, researchers reported that 
younger age, greater severity of myopia, and faster 
progression were risk factors of progression for a 
subgroup of children despite receiving atropine 
treatment (110). The five-year results of the ATOM 2 
study were published recently. After receiving atropine 
at different concentrations for 24 months (phase 1), 
individuals received no treatment for 12 months. 
Children who presented with myopia progression > 0.50 
D were then restarted on 0.01% atropine therapy for a 
further 24 months. As 0.01% atropine showed the lowest 
rebound effect, it was the most effective concentration 
to reduce the progression of myopia at three and five 
years, with five-year overall change of -1.38 D, compared 
with -1.83 D in the 0.1% group and -1.98 D in the 0.5% 
group (111). However, when considering all children that 
received 0.1% atropine or 0.01% atropine compared to 
those who received 0.5%, atropine there were significant 
differences in progression during the first year; slower 
progression was observed in the 0.5% group. In terms of 
progression during the second year, when comparing all 
children who received 0.01% atropine versus those who 
received 0.5%, the difference was not significant, nor was 
significant in the same period among those who received 
0.1% atropine versus those who received 0.5%. These 
results suggest that a promising approach would be for 
myopic children to use a more concentrated atropine 
solution (0.5%) during the first year and a lower 
concentration (0.01%) the second year (112). 
In 2012, we suggested that applying one eye drop every 
week, in comparison with one per day, would facilitate 
compliance among young patients. Our study used 1.0% 
atropine once per week in conjunction with 
photochromatic progressive addition lenses (PAL) and 
ocular hypotensive eye drops, was well tolerated by the 
patients, and was very effective at stopping myopia 
progression (113). In a group of 33 patients (66 eyes) 
aged 6 to 16 years (mean, 11.9 years) treated with ocular 
hypotensive drops, the baseline spherical equivalent was 
-4.52 D. At the one-year follow-up, the spherical 
equivalent was -4.46 D (P = 0.015). This slight reduction 
of the magnitude of myopia was attributed to the 
hyperopic shift secondary to the cycloplegic effect of 
atropine. Progression was essentially zero (113). 
As lower concentrations of atropine have been shown to 
be effective, and considering that the effect can last for 
up to 2 weeks, we suggest that a future study should 
investigate a course of treatment that uses 0.5% atropine 
therapy once or twice per week for one year, which is 
then changed to 0.01% atropine administered daily (112). 
Modern studies outside Asia have also reported good 
outcomes. Polling et al. (2016) studied 77 myopic 
children of diverse ethnicity (European, Asian, and 
African) who received 0.5% atropine eye drops every day. 
Sixty children received the treatment for 12 months. The 
most common adverse events were photophobia (72%), 
reading  difficulties (38%), and headache (22%). Myopia 
progression before treatment was −1.0 D/year ± 0.7, and 
drastically diminished during the treatment period to 
−0.1 D/year ± 0.7. Those children who stopped the 
therapy had a progression of −0.5 D/year ± 0.6 (114). 
Several meta-analyses have been performed on this topic 
in the past six years. Walline et al. (2011) concluded that 
the most probable effective treatment to diminish 
myopia progression was anti-muscarinic eye drops. 
However, side effects and unavailability limited clinical 
use (115). Song et al. (2011) published a meta-analysis of 
six randomized clinical trials that analyzed the annual 
rate of myopia progression after daily atropine 
application over one year. They concluded that lower 
concentrations (0.05%, 0.1%, and 0.25%) of atropine 
were not effective because myopia may still progress 
during use. However, when higher concentrations were 
used (0.5% and 1%), the progression was controlled for 
between 6 and 24 months in the diverse studies (116). 
Another meta-analysis by Li et al. (2014) concluded that 
atropine could significantly slow myopia progression in 
children, but showed greater effects in Asian than in 
Caucasian children. The weighted mean differences in 
myopia progression between treated and control groups 
in cohort studies and clinical trials including Asian 
children were 0.54 D per year and 0.55 D per year, 
respectively. Progression was smaller (0.35 D per year) in 
cohort studies including Caucasian children (117). In 
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2016, Huang et al. published their network meta-analysis 
of interventions for myopia treatment. They included 30 
clinical trials in the analysis (5422 eyes) and performed a 
random effects network meta-analysis combining direct 
and indirect evidence. When comparing mean annual 
change in refraction (diopters/year) and mean annual 
change in axial length (millimeters/year) with placebo or 
single-vision eyeglasses, they found that 1.0% and 0.5% 
atropine (refraction change: 0.68 D; axial length change: -
0.21 mm); 0.1% atropine (refraction change: 0.53 D; axial 
length change: -0.21 mm) and 0.01% atropine (refraction 
change: 0.53 D; axial length change: -0.15 mm) markedly 
slowed myopia progression. However, on direct 
comparison, 1.0% and 0.5% atropine had slightly higher 
effects compared to 0.01% atropine (refraction change: 
0.10 D; axial length change: -0.07 mm) (118). 
A clear advantage of very low atropine concentration is 
tolerance. Several studies have shown that side effects of 
low-concentration atropine are very uncommon. In 2011 
Wu et al. published the results of a retrospective, case-
control study including 117 children who received 0.05% 
atropine, and if progression of more than -0.5 D during a 
6-month follow-up was observed, were changed to 0.1% 
atropine and were followed for at least 3 years. No side 
effects were reported (107). The ATOM 2 study reported 
that upon restarting 0.01% atropine in children who 
showed progression after a 12-month atropine washout 
(n = 192), there was a mean increase in photopic pupil 
size of approximately 1 mm and a loss of accommodation 
of 2.00 to 3.00 D, which were similar to the changes 
observed when the children were initially assigned to 
0.01% atropine during phase 1. These ocular side effects 
were considered clinically insignificant. Children were 
offered progressive addition or photochromatic (tinted) 
glasses if they had problems with near vision when using 
the single vision eyeglasses, or experienced glare. During 
phase 1, 7% of children receiving 0.01% atropine 
requested such glasses, but no child who had restarted 
0.01% atropine requested glasses. Pupil size and 
accommodation returned to levels similar to those in 
untreated children when examined two months after 
cessation of 0.01% atropine (111). In 2013 Cooper et al. 
performed a phase I clinical trial including 12 children 
with brown irises (one eye included in the study group 
and the fellow eye used as control), and found that 
0.02% atropine was the maximum concentration that 
could be administered daily without a clinical effect, 
having defined the target toxicity level as an 
accommodative amplitude below 5 D, a difference in 
pupillary diameter equal to or greater than 3 mm, and/or 
a failure to read very small print (J1) while wearing 
distance correction (119). Nishiyama et al. found that 
although accommodation decreased by a mean of 1.5 D 
and the pupil diameter increased in size by mean 0.7 
mm, the subjective symptoms of a group of 16 children 
receiving 0.01% atropine eye drops daily were minimal 
after two weeks (120). Recently, Loughman and Flitcroft 
performed a tolerance study on 14 young Caucasian 
adults in Ireland, who received one drop of 0.01% 
atropine in both eyes every day for five days. Photopic 
pupil size increased between 1.08 and 1.31 mm and 
amplitude of accommodation decreased slightly; 
however, there were no negative effects on visual acuity 
or reading speed. Although there was a slight increase in 
glare, there was no significant negative impact on quality 
of life, which was associated with low-dose topical 
atropine (0.01%) (121). 
The effectiveness of the lowest atropine concentration 
(0.01%) in the ATOM 2 study has been replicated outside 
Asia (111). A retrospective case-control study performed 
by Clark and Clark on 60 children (ethnically diverse in 
the United States) used 0.01% atropine and found 
diminished rates of myopic progression after one year (-
0.1 D/year) compared to no medication (-0.6 D/year). 
However, despite receiving atropine, three patients 
experienced rapid myopic progression (122). 
Additionally, low-concentration atropine has 
demonstrated some effect in the prevention of myopia 
onset in children who do not yet present it (pre-myopic). 
Atropine (0.025%) was administered to children aged 6 
to 12 years with a spherical equivalent between +1.00 
and -1.00 D, who were followed for at least 12 months. 
Twenty-one percent of the children receiving atropine 
became myopic, compared to 54% of those in a control 
group (123). 
In summary, robust evidence supports atropine use to 
slow the progression of myopia. Some concerns 
regarding long-term safety have not yet been resolved. 
However, the general consensus of the clinical studies is 
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that the treatment is safe. Lower concentrations (0.01%, 
0.1%) are better tolerated and could be a very good 
option in clinical practice (111, 122, 124). However the 
weaker efficacy could be a concern (116). A once- or 
twice-a-week application could be an alternative 
treatment option for the use of high-concentration 
atropine (0.5% or 1.0%) (112, 113).  
Currently, the prescription of atropine eye drops in 
myopic children has not yet become standard practice in 
the Western hemisphere; it is commonly used in Asian 
countries such as Taiwan and Singapore, and has been 
recommended for more than 15 years by the 
Ophthalmological Society of Taiwan as a therapeutic 
alternative to slow myopia progression (124-126). Now 
may be the time to begin the use of this therapeutic 
alternative in daily clinical practice around the world. 
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